Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
Crossref DOI link: https://doi.org/10.1007/s10147-021-02018-3
Published Online: 2021-09-09
Published Print: 2021-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sekine, Masayuki http://orcid.org/0000-0003-0751-6395
Enomoto, Takayuki
Watanabe, Yoh
Katabuchi, Hidetaka
Yaegashi, Nobuo
Aoki, Daisuke
Text and Data Mining valid from 2021-09-09
Version of Record valid from 2021-09-09
Article History
First Online: 9 September 2021